On July 22, Ionis Pharmaceuticals declined 5.16% in regular trading, trading at $51.69/share, with turnover of $40.30 million. The decline reflects continued selling pressure from multiple negative catalysts.

On the news front, the stock remains under pressure following the July 9 disclosure that Eplontersen, co-developed with AstraZeneca for transthyretin-mediated amyloid cardiomyopathy, failed to meet its primary endpoint in the Phase 3 Cardio-Ttransform trial at week 140. That event triggered a single-day plunge exceeding 20%. Subsequently, RBC cut its price target from $100 to $85 while maintaining an Outperform rating, and TD Cowen lowered its target from $108 to $94 while keeping a Buy rating.

Additionally, with the next earnings report scheduled for July 29, analysts have adopted a cautious near-term stance, citing uncertainty around collaboration milestones and expense rigidity that may pressure both revenue and margins. The combination of the cardiovascular pipeline setback, target price reductions, and pre-earnings uncertainty continues to suppress the stock in the near term.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)